IL297642A - Methods for using t-type calcium channel modulators - Google Patents
Methods for using t-type calcium channel modulatorsInfo
- Publication number
- IL297642A IL297642A IL297642A IL29764222A IL297642A IL 297642 A IL297642 A IL 297642A IL 297642 A IL297642 A IL 297642A IL 29764222 A IL29764222 A IL 29764222A IL 297642 A IL297642 A IL 297642A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- dose
- subject
- dynamicpdf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transmitters (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017140P | 2020-04-29 | 2020-04-29 | |
| US202063050410P | 2020-07-10 | 2020-07-10 | |
| US202063082946P | 2020-09-24 | 2020-09-24 | |
| PCT/US2021/029539 WO2021222342A1 (en) | 2020-04-29 | 2021-04-28 | Methods of use of t-type calcium channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297642A true IL297642A (en) | 2022-12-01 |
Family
ID=78373913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297642A IL297642A (en) | 2020-04-29 | 2021-04-28 | Methods for using t-type calcium channel modulators |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12697331B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4142764A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023524039A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230018384A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115776894A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021263804A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022021946A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177277A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297642A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013595A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021222342A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021007487A1 (en) | 2019-07-11 | 2021-01-14 | Praxis Precision Medicines, Inc. | Formulations of t-type calcium channel modulators and methods of use thereof |
| CA3243616A1 (en) * | 2022-02-03 | 2023-08-10 | Praxis Precision Medicines, Inc. | TREATMENT METHODS USING T-TYPE CALCIUM CHANNEL MODULATORS |
| WO2023192885A2 (en) * | 2022-03-28 | 2023-10-05 | Praxis Precision Medicines, Inc. | Methods of using oligomeric compounds to treat scn2a-related disorders |
| US20250295646A1 (en) * | 2022-05-09 | 2025-09-25 | Praxis Precision Medicines, Inc. | Methods of use of t-type calcium channel modulators |
| CN121127457A (zh) * | 2023-03-02 | 2025-12-12 | 普拉西斯精密医药公司 | T型钙通道调节剂的结晶盐和其使用方法 |
| AU2024230578A1 (en) * | 2023-03-02 | 2025-09-04 | Praxis Precision Medicines, Inc. | Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide and methods of use thereof |
| WO2025059511A1 (en) | 2023-09-15 | 2025-03-20 | Praxis Precision Medicines, Inc. | Elsunersen / prax-222 for use in the treatment of scn2a-related disorders |
| WO2025188619A1 (en) * | 2024-03-04 | 2025-09-12 | Praxis Precision Medicines, Inc. | Methods of treating parkinson's disease with t-type calcium channel modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377968B2 (en) * | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| EP3364993B1 (en) * | 2015-10-22 | 2022-11-09 | Cavion, Inc. | Methods for treating angelman syndrome |
| RU2746188C2 (ru) * | 2015-11-12 | 2021-04-08 | Афаски, Инк. | Ингибиторы ионного канала, фармацевтические составы и применение |
| HRP20220463T1 (hr) * | 2016-12-16 | 2022-05-27 | Idorsia Pharmaceuticals Ltd | Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa |
| WO2018118101A1 (en) * | 2016-12-21 | 2018-06-28 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| SG11202004329TA (en) * | 2017-11-10 | 2020-06-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
| JP7480131B2 (ja) * | 2018-10-03 | 2024-05-09 | カビオン・インコーポレイテッド | (r)-2-(4-イソプロピルフェニル)-n-(1-(5-(2,2,2-トリフルオロエトキシ)ピリジン-2-イル)エチル)アセトアミドを使用した本態性振戦の処置 |
| WO2021007487A1 (en) * | 2019-07-11 | 2021-01-14 | Praxis Precision Medicines, Inc. | Formulations of t-type calcium channel modulators and methods of use thereof |
| US20250295646A1 (en) * | 2022-05-09 | 2025-09-25 | Praxis Precision Medicines, Inc. | Methods of use of t-type calcium channel modulators |
-
2021
- 2021-04-28 CN CN202180046763.8A patent/CN115776894A/zh active Pending
- 2021-04-28 JP JP2022566066A patent/JP2023524039A/ja active Pending
- 2021-04-28 IL IL297642A patent/IL297642A/en unknown
- 2021-04-28 KR KR1020227041859A patent/KR20230018384A/ko active Pending
- 2021-04-28 AU AU2021263804A patent/AU2021263804A1/en active Pending
- 2021-04-28 BR BR112022021946A patent/BR112022021946A2/pt unknown
- 2021-04-28 WO PCT/US2021/029539 patent/WO2021222342A1/en not_active Ceased
- 2021-04-28 EP EP21795254.8A patent/EP4142764A4/en active Pending
- 2021-04-28 CA CA3177277A patent/CA3177277A1/en active Pending
- 2021-04-28 MX MX2022013595A patent/MX2022013595A/es unknown
-
2022
- 2022-10-27 US US17/975,457 patent/US12697331B2/en active Active
-
2026
- 2026-05-26 JP JP2026087958A patent/JP2026127654A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021263804A1 (en) | 2023-01-19 |
| MX2022013595A (es) | 2023-01-24 |
| CN115776894A (zh) | 2023-03-10 |
| JP2023524039A (ja) | 2023-06-08 |
| BR112022021946A2 (pt) | 2023-01-17 |
| US12697331B2 (en) | 2026-08-04 |
| KR20230018384A (ko) | 2023-02-07 |
| JP2026127654A (ja) | 2026-08-06 |
| CA3177277A1 (en) | 2021-11-04 |
| EP4142764A1 (en) | 2023-03-08 |
| EP4142764A4 (en) | 2024-05-29 |
| WO2021222342A1 (en) | 2021-11-04 |
| US20230165847A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12077502B2 (en) | Formulations of T-type calcium channel modulators and methods of use thereof | |
| US20230165847A1 (en) | Methods of use of t-type calcium channel modulators | |
| US20250295646A1 (en) | Methods of use of t-type calcium channel modulators | |
| IL279220B2 (en) | Use of (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders | |
| TW201110967A (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| US20250375380A1 (en) | High strength single unit dose formulations and methods of use thereof | |
| US20250170114A1 (en) | Methods of treatment using t-type calcium channel modulators | |
| IL319372A (en) | Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders |